deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-31. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for reconstituted peptides vary by sequence and intended use, so general rules remain broad. A common laboratory practice is to keep solutions cold, sometimes frozen, and protected from light, but freezing itself can damage certain peptides. The pH of the solution may be adjusted to a range where the peptide is most stable, though changing pH can also alter solubility. Documentation of reconstitution date, solvent, concentration, and storage conditions supports reproducibility. Stability data for a specific peptide are generally established by direct measurement rather than assumed from related compounds.
Once a peptide is in solution, its stability depends on temperature, pH, ionic strength, and the presence of oxygen or light. Many peptides are less stable in liquid form than as dry powders because hydrolysis, oxidation, and aggregation can proceed faster in water. Storage at low temperature slows these reactions but does not eliminate them. Some sequences are particularly sensitive to repeated freezing and thawing, which can cause precipitation or conformational changes. The container material and headspace also influence adsorption and surface-induced aggregation.
Aseptic technique is used when a reconstituted solution must remain free of microbial contamination. Work surfaces, gloves, and instruments are cleaned, and the septum of a vial is disinfected before solvent is added. A venting needle or pressure equalization can prevent aerosol formation and pressure buildup. Bacteriostatic water contains an antimicrobial preservative, but preservatives can interfere with some assays or alter peptide behavior. Sterile filtration may be used when a formulation cannot be heat sterilized or when particulates must be removed.
Quality control for reconstituted peptides includes recording lot number, solvent, date, and storage conditions. Visual inspection checks clarity, color, and particles, while pH measurement verifies the expected solution environment. Concentration is often estimated by ultraviolet absorbance at 280 nm for peptides containing tryptophan or tyrosine, or by high-performance liquid chromatography. Mass spectrometry can confirm molecular identity before reconstitution. Sterility testing is relevant when microbial contamination would invalidate an experiment, though such testing is not routinely performed in every laboratory.
Once a peptide is dissolved, water becomes a medium for hydrolysis, oxidation, and deamidation. Dry powders often tolerate ambient shipping better than liquid solutions, but the exact stability profile depends on sequence and formulation. Refrigerated storage near 2 to 8 degrees Celsius or frozen storage at minus 20 or minus 80 degrees Celsius is common in laboratories. Repeated freeze-thaw cycles can promote aggregation, precipitation, or loss of activity. Dividing a solution into single-use aliquots before freezing can reduce the number of temperature cycles.
| Property | Value | Notes |
|---|---|---|
| Solution appearance | Clear to slightly opalescent | Cloudiness can signal aggregation or undissolved material. |
| Typical short-term storage | 2-8 °C | Refrigeration is common for solutions used within a short period. |
| Typical long-term storage | -20 °C or lower | Freezing may require aliquoting to avoid repeated freeze-thaw cycles. |
| Common container | Low-binding plastic or glass vial | Low-binding surfaces can reduce adsorptive loss. |
| Common preservative | Bacteriostatic water | Contains an antimicrobial agent; not compatible with all analytical workflows. |
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
Once a peptide is dissolved, its solution is generally less stable than the dry powder. Chemical pathways such as hydrolysis, oxidation, and deamidation can alter the molecule, while physical processes can form aggregates or cause adsorption to container walls. The rate depends on pH, buffer composition, temperature, concentration, and the specific sequence. Aqueous stocks are therefore kept cold and used within a defined period. Stability testing is usually performed for each peptide rather than assumed from a general rule.
Dissolution involves hydration of polar and charged groups, disruption of intermolecular interactions in the lyophilized powder, and transition to a thermodynamically favored solution state. Not all powder dissolves readily; aggregation, incomplete lyophilization, or high molecular weight can slow reconstitution. The resulting solution may contain particulates or oligomers that affect downstream measurements. Researchers often verify complete dissolution by visual inspection and spectrophotometric or chromatographic methods. The relationship between reconstitution conditions and long-term stability remains an active area of study.
Peptide reconstitution is the process of dissolving a lyophilized peptide powder in a liquid solvent to produce a solution of defined concentration. Lyophilization removes water under vacuum from a frozen peptide solution, leaving a porous cake or powder. The dry form is often more stable for shipping and storage. Reconstitution restores the peptide to a liquid state for analytical, biochemical, or formulation work. The exact solvent depends on peptide sequence and intended assay.
After a solvent is added, the vial is typically swirled or gently inverted rather than shaken vigorously. Shaking can introduce air and shear forces that promote foaming or aggregation, especially for longer peptides. Dissolution may take several minutes, and the solution should become clear unless the peptide is intentionally in suspension. Concentration is calculated from the mass of peptide stated on the vial label divided by the total liquid volume. If the dried peptide contains salts or counterions, the actual peptide content may be lower than the nominal mass.
Reconstitution is the process of adding a liquid to a lyophilized peptide so that the dried material dissolves into solution. Lyophilization removes water from a frozen peptide preparation under reduced pressure, leaving a porous solid or powder. The dried form often has greater long-term stability than a liquid because hydrolysis and oxidation are slowed. In laboratory work, reconstitution is usually the first step before dilution, analysis, or further experiments. The result is a stock solution whose concentration depends on the volume of solvent added and the amount of peptide in the vial.
Solvent choice depends on the peptide's sequence, charge, and solubility profile. Sterile water is common for freely soluble peptides, while aqueous buffers or dilute acid or base may be needed for others. Some sequences contain hydrophobic regions that resist water alone and require a small amount of organic co-solvent. The solvent's pH can affect charge state, aggregation, and stability. Because peptides vary widely, no single universal reconstitution liquid exists, and suppliers often provide a recommended solvent based on testing of a specific lot or sequence.
From the perspective of its commercial promoters, scientific breakthroughs, industrial commitment, and official support were finally coming together, and biotechnology became a normal part of business. No longer were the proponents for the economic and technological significance of biotechnology the iconoclasts. Their message had finally become accepted and incorporated into the policies of governments and industry.
=== In mines === 222Rn decay products have been classified by the International Agency for Research on Cancer as being carcinogenic to humans, and as a gas that can be inhaled, lung cancer is a particular concern for people exposed to elevated levels of radon for sustained periods. During the 1940s and 1950s, when safety standards requiring expensive ventilation in mines were not widely implemented, radon exposure was linked to lung cancer among non-smoking miners of uranium and other hard rock materials in what is now the Czech Republic, and later among miners from the Southwestern US and South Australia. Despite these hazards being known in the early 1950s, this occupational hazard remained poorly managed in many mines until the 1970s. During this period, several entrepreneurs opened former uranium mines in the US to the general public and advertised alleged health benefits from breathing radon gas underground. Health benefits claimed included relief from pain, sinus problems, asthma, and arthritis, but the government banned such advertisements in 1975, and subsequent works have debated the truth of such claimed health effects, citing the documented ill effects of radiation on the body. Since that time, ventilation and other measures have been used to reduce radon levels in most affected mines that continue to operate. In recent years, the average annual exposure of uranium miners has fallen to levels similar to the concentrations inhaled in some homes.
Erythroferrone is a protein hormone encoded in humans by the ERFE gene. Erythroferrone is produced by erythroblasts, inhibits the production of hepcidin in the liver, and so increases the amount of iron available for hemoglobin synthesis. Skeletal muscle secreted ERFE has been shown to maintain systemic metabolic homeostasis.
A new Media Act was passed into law in 1967, merging the NRU and the NTS. The new organisation, the Nederlandse Omroep Stichting (Netherlands Broadcasting Service; NOS) was created on 29 May 1969. The NOS, as were its predecessors, was tasked with coordinating the whole public broadcasting system, as well as providing news and sports bulletins. It also inherited the technical and production facilities needed to make and broadcast radio and television programmes. All broadcasting members of the NRU and the NTS were made members of the NOS. By 1971 seven programming societies existed, each receiving part of the television licence fee and advertising revenue. Because of pillarization most represented various political and religious groups, although the largest, AVRO, was the most neutral. Twenty-seven smaller groups such as the Society for Sexual Reform received small time slots, as well as all parties represented in the Dutch Parliament. Societies produced their own programs, and purchased others from abroad. Besides news and sports, NOS produced children and educational programs for the one third of broadcast hours it filled. On 2 May 1977, a strike by sound engineers affected television news broadcasts. Upset viewers called on all broadcasters to resolve the situation. On 1 April 1980, the NOS launched its teletext service, in the framework of supplying news and information. It first experimented with Teletext in 1977. In 1981, on the 25th anniversary, the NOS aired its first televised youth news bulletin, called Jeugdjournaal.
Sources: en.wikipedia.org
Administration a 100 mg/m2 dose over a one-hour infusion gave a mean total body clearance of 21 L/h/m2 and a mean steady state volume of distribution of 73.8 L/m2 or 123 L based on the mean BSA (body surface area) of 1.68 m2. Area under the plasma concentration-time curve had a mean value of 2.8 mg.h/L. The Cmax of docetaxel was found to be 4.15 ± 1.35 mg/L. Increased dose resulted in a linear increase of the area under the concentration-time curve and so it is concluded that dose is directly proportional to plasma concentration.
Hooker Hamersley (1865), heir, lawyer, and poet; former president of the Knickerbocker Club Shipley Jones (1868), banker and clubman William Bayard Cutting (1869), financier, philanthropist, namesake of the Bayard Cutting Arboretum State Park Robert Fulton Cutting (1871), financier George Beach de Forest Jr. (1871), capitalist, bibliophile, and art collector Stuyvesant Fish (1871), president of the Illinois Central Railroad James Montaudevert Waterbury Sr. (1873), industrialist, co-founder of the New York Yacht Club Isaac Newton Seligman (1876), heir to investment bank J. & W. Seligman & Co. T. J. Oakley Rhinelander (1878), heir and real estate developer who owned the Schönburg castle in Germany William Fellowes Morgan Sr. (1880), businessman, philanthropist George Henry Warren II (1880), stockbroker and real estate developer who co-founded the Metropolitan Opera and Real Estate Company Eugene Higgins (1882), heir and philanthropist Lewis Morris Rutherfurd Jr. (1882), socialite and sportsman Marshall Orme Wilson (1882), banker and socialite, son-in-law of William Backhouse Astor Jr. George M. La Monte* (1884), chairman of Prudential Financial 1925–1927 Joseph P. Knapp* (1884), businessman, philanthropist, founder of Ducks Unlimited Temple Bowdoin (1885), former executive of J.P. Morgan & Co. Benjamin Guggenheim* (1887), businessman, son of Meyer Guggenheim and member of the Guggenheim family Richard Thornton Wilson Jr.
Between her second and third flights, Caldwell Dyson continued to work inside Houston’s Mission Control Center as CAPCOM for both space shuttle and space station operations, serving as the lead CAPCOM for various ISS missions, including the lead and development of the CAPCOM cadre for Boeing Starliner Mission Operations team. She was also the ground IV for US EVA 32, performed by Scott Kelly and Kjell Lindgren. Caldwell Dyson initiated and led several projects to improve training and operations aboard the ISS, most notably developing the EVA Qualification training flow (EVQ) for astronaut candidates. After her third trip to space, she served as the ground IV for US EVA 95, performed by Jessica Meir and Christopher Williams in March 2026. She also worked as one of the CAPCOM for the Artemis II mission, working during 3 separate shifts. During the summer 2026 with the European Space Agency, she participated in the CAVES training program with her NASA astronaut colleague, Ben Bailey and astronauts from other agencies John McFall, Ayu Yoneda and Rosemary Coogan. As Tracy Dyson, she is the host of a series on NASA TV called StationLife, which focuses on facets of life aboard the International Space Station. On March 21, 2017, Caldwell Dyson stood behind President Trump as he signed a bill for NASA to send humans to Mars in the 2030s and receive $19.5 billion in 2018 funding. Caldwell Dyson and fellow NASA astronaut Chris Cassidy presented Trump with an official flight jacket during the ceremony.
Widespread use Spironolactone — the first and most widely used member of this class Eplerenone — much more selective than spironolactone on target, but somewhat less potent and efficacious Uncommon use (to date) Canrenone and potassium canrenoate — very limited use Finerenone — nonsteroidal and more potent and selective than either eplerenone or spironolactone Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, metribolone, and benidipine.
== Select publications == Masur, S.K. (1969). "Fine structure of the autotransplanted pituitary of the red eft. Notophthalmus viridescens". Gen. Comp. Endocrin. 12: 12–32. Masur, S.K.; Holtzman, E.; Schwartz, I.L.; Walter, R. (1971). "Correlation between pinocytosis and hydroosmosis induced by neurohypophyseal hormone and mediated by adenosine 3', 5'-cyclic monophosphate". J. Cell Biol. 49: 582–589. Masur, S.K.; Dewal, H.S.; Dinh, T.T.; Erenburg, I.; Petridou, S. (1996). "Myofibroblasts differentiate from fibroblasts plated at low density". Proc. Natl. Acad. Sci. 93: 4219–4223. Maltseva, O; Folger, P; Zekaria, D; Petridou, S; Masur, SK (2001). "Fibroblast growth factor reversal of the corneal myofibroblast phenotype". Invest Ophthalmol Vis Sci. 42: 2490–5. PMID 11581188.. Masur, S.; Kane, C. M. (2001-12-21). "Tapping science's women for the podium". Science. 294 (5551): 2480. doi:10.1126/science.294.5551.2480a. ISSN 0036-8075. PMID 11770518.. Bernstein, AM; Twining, SS; Warejcka, DJ; Tall, E; Masur, SK (2007). "Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation". Mol Biol Cell. 18: 2716–27. doi:10.1091/mbc.e06-10-0912. PMC 1924808. PMID 17507651.. Masur, Sandra Kazahn (January 2013). "Women in cell biology: a seat at the table and a place at the podium". Molecular Biology of the Cell. 24 (2): 57–60. doi:10.1091/mbc.E12-07-0517. ISSN 1939-4586. PMC 3541963. PMID 23307103.. Masur, Sandra K. (2015-08-01). "Invisible woman?". Trends in Cell Biology. 25 (8): 437–439. doi:10.1016/j.tcb.2015.06.001. ISSN 0962-8924.
Sources: en.wikipedia.org
=== Popular opposition and regional rebellions === Research suggests that protests spur coups, as they help elites within the state apparatus to coordinate coups. A 2019 study found that regional rebellions made coups by the military more likely.
=== Discontinued === 2-BUMP – monoamine oxidase B (MAO-B) inhibitor [238] A-77636 – dopamine D1 receptor agonist [239] Acamprosate/baclofen (PXT-864) – combination of acamprosate (various actions) and baclofen (GABAB receptor agonist) [240] Adrogolide (ABT-431; DAS-431; A-86929 O,O′-diacetate) – dopamine D1 receptor agonist (prodrug of A-86929) [241] AP-001 – various actions [242] Apomorphine inhalation (VR-004; VR-040; VR-400) – non-selective dopamine receptor agonist and other actions [243] Apomorphine intranasal – non-selective dopamine receptor agonist and other actions [244] Apomorphine subcutaneous (ND-0701) – non-selective dopamine receptor agonist and other actions [245] Apomorphine transdermal patch – non-selective dopamine receptor agonist and other actions [246] Arimoclomol (BRX-345; Miplyffa; OR-01; OR-04) – undefined mechanism of action [247] Arundic acid (Arocyte Injection; Cereact Capsule; MK-0724; ONO-2506; Proglia) – various actions [248] Atomoxetine (LY-139603; Strattera; Tomoxetine) – norepinephrine reuptake inhibitor (NRI) [249] AVE-8112 (AVE8112; AVE-8112A) – phosphodiesterase PDE4 inhibitor [250] AX-201 (AX201) – nerve growth factor (NGF) stimulant [251] Bifeprunox (DU-127090) – serotonin 5-HT1A receptor agonist and dopamine D2 receptor agonist [252] BP-897 – dopamine D3 receptor agonist [253] Carbidopa/levodopa (AP-09004; AP-CD/LD) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [254] CEP-1347 (KT-7515) – mitogen-activated protein kinase inhibitor and mixed-lineage kinase inhibitor [255] CERE-120 (AAV-NRTN; AAV-NTN; AAV2-neurturin; AAV2-NTN; neurturin gene therapy) – gene therapy, nerve tissue protein modulator, and neurturin agonist [256] Cinpanemab (BIIB-054) – monoclonal antibody against α-synuclein [257] CVXL-0107 – glutamate release inhibitor [258] Dactolisib (BEZ-235; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101) – 1-phosphatidylinositol 3 kinase inhibitor and mTOR inhibitor [259] Davunetide intranasal (AL-108; NAP; NAPVSIPQ) – various actions [260] Dihydrexidine (DAR-0100) – dopamine D1 receptor agonist [261] Dihydrexidine (IP-202) – dopamine D1 and D5 receptor agonist [262] DNS-7801 – undefined mechanism of action [263] Embryonic neural cell therapy-Parkinson's Disease - CellFactors (Parkinson's disease cell therapy) – dopaminergic cell replacement [264] Emlenoflast (inzomelid; IZD-174; MCC-7840) – NLR family pyrin domain containing 3 (NLRP3) inhibitor [265] Entacapone (Comtan; Comtess; OR-611) – catechol O-methyltransferase (COMT) inhibitor [266] Ethyl eicosapentaenoic acid (AMR-101; Ethyl-EPA; LAX-101; Miraxion; Vascepa; Vazkepa) – various actions [267] Etrabamine (14-839JL; JL-14839) – dopamine D2 receptor agonist [268] Ezaladcigene resoparvovec (AAV-AADC; AV-201; GZ-404477; NBIb-1817) – gene transference and aromatic-L-amino-acid decarboxylase (AAAD) replacement [269] Fipamezole (BVF-025; JP-1730) – α2-adrenergic receptor antagonist [270] Florbenazine F18 (18F-DTBZ; 18F-AV-133; 18F-FP-dihydrotatetrabenazine; AV-133) – vesticular monoamine transporter 2 (VMAT2) inhibitor and radiopharmaceutical – diagnosis [271] Foliglurax (PXT-2331; PXT002331) – metabotropic glutamate mGlu4 receptor positive allosteric modulator [272] FRM-0334 (EVP-0334) – class I and class II histone deacetylase inhibitor [273] GYKI-52895 – dopamine reuptake inhibitor (DRI) [274] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) modulator [275] Lu-AA47070 (LU-AA-47070) – adenosine A2A receptor antagonist [276] Methylthioninium chloride (MTC; methylene blue; TRx-0014; TRx-014) – various actions [277] Naxagolide (L-647339) – dopamine D2 and D3 receptor agonist [278] Nebicapone (BIA-3202) – catechol O-methyltransferase (COMT) inhibitor [279] Nitecapone (OR-462) – catechol O-methyltransferase (COMT) inhibitor Nitisinone (NTBC; Orfadin; SC-0735; SYN-118) – 4-hydroxyphenylpyruvate dioxygenase inhibitor and dopamine release stimulant [280] NPT-088 (NPT088) – immunoglobulin fusion general amyloid interaction motif (GAIM) based dimer [281] NPT-189 (NPT189) – immunoglobulin fusion protein [282] NW-1048 – monoamine oxidase B (MAO-B) inhibitor [283] NYX-458 – ionotropic glutamate NMDA receptor positive allosteric modulator [284] ODM-103 – catechol O-methyltransferase (COMT) inhibitor [285] Omigapil (CGP-3466; SNT-317; TCH-346) – glyceraldehyde 3 phosphate dehydrogenase (GAPDH) inhibitor [286] OPM-201 (S-221237) – leucine-rich repeat kinase 2 (LRRK2) inhibitor [287] OSU-6162 (OSU6162; PNU-9639; PNU-96391; PNU-96391A) – serotonin 5-HT2A receptor partial agonist (non-hallucinogenic), dopamine D2 receptor partial agonist, and sigma σ1 receptor ligand (so-called "monoaminergic stabilizer") [288] Paliroden (SR-57667; SR-57667B) – nerve growth factor (NGF) stimulant [289] Pardoprunox (SLV-308; SME-308) – dopamine D2 and D3 receptor partial agonist, serotonin 5-HT1A receptor full agonist, and other actions [290] Parkinson's disease gene therapy - Oxford BioMedica (AXO Lenti PD; OXB-101; OXB-102; ProSavin) – gene transference [291] Pegipanermin (DN-TNF; INB-03; LIVNate™; Quellor™; soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTM) – tumour necrosis factor alpha (TNFα) inhibitor and immunostimulant [292] PF-06412562 (CVL-562) – dopamine D1 and D5 receptor partial agonist [293] Piclozotan (SUN-4057; SUN-N-4057) – serotonin 5-HT1A receptor agonist – dyskinesia in Parkinson's disease [294] Preclamol ((–)-3-PPP) – dopamine D2 receptor partial agonist [295] Preladenant (MK-3814; privadenant; SCH-420814) – adenosine A2A receptor antagonist [296] Proxison – synthetic flavonoid-based antioxidant [297] Quinelorane (LY-163502) – dopamine D2 receptor agonist [298] Raseglurant (ADX-10059) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [299] Razpipadon (CVL-871; PF-6669571; PF-06669571; PW-0464) – dopamine D1 receptor agonist [300] Renzapride (ATL-1251; AZM-112; BRL-24924) – serotonin 5-HT3 receptor antagonist and serotonin 5-HT4 receptor agonist [301] Research programme: Alzheimer's and Parkinson's disease diagnostic agents - Bayer HealthCare Pharmaceuticals/TauRx – undefined mechanism of action – diagnosis [302] Research programme: AMC therapeutics - Animuscure – undefined mechanism of action [303] Research programme: Ig fusion GAIM dimers - Proclara Biosciences (NPT-288; NPT-007; NPT-014; NPT-289) – various actions [304] Research programme: Parkinson's disease therapeutics - Araclon Biotech (AB-03) – undefined mechanism of action [305] Research programme: Parkinson's disease therapies - Neose/Neuronyx – undefined mechanism of action [306] Research programme: Parkinson's disease therapies - Proteome Systems (EUK-418) – free radical scavenger and oxygen radical scavenger [307] Research programme: Parkinson's disease therapeutics - TauRx Therapeutics (G2 PD; TRx 018) – synuclein inhibitor [308] Research programme: protein aggregation inhibitors - Proclara Biosciences (NPT-001; NPT-002) – various actions [309] Riluzole (PK-26124; Rilutek; RP-54274) – various actions [310] Ropinirole implant – dopamine D2, D3, and D4 receptor agonist [311] Sarsasapogenin (Cogane; JNX-1001; PYM-50028; Smilagenin) – various actions [312] Sipagladenant (KW-6356) – adenosine A2A receptor antagonist [313] SPD-474 – undefined mechanism of action [314] Sumanirole (PNU-95666; U-95666) – dopamine D2 receptor agonist [315] TAK-065 – undefined mechanism of action [316] TAK-071 – muscarinic acetylcholine M1 receptor positive allosteric modulator [317] Tc 99m TRODAT-1 – single-photon emission-computed tomography (SPECT) enhancer – diagnosis [318] Terguride (Dironyl; Mysalfon; SH-406; Teluron; transdihydrolisuride; VUFB-6638; ZK-31224) – dopamine D2 receptor agonist and other actions [319] Tozadenant (A2a-(3); RO4494351; SYN-115) – adenosine A2A receptor antagonist [320] Utreloxastat (EPI-857; PTC-857) – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [321] Vipadenant (BG-14; BIIB-014; BIIB14; CEB-4520; V-2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006) – adenosine A2A receptor antagonist [322] [323]
Gonadotropin-releasing hormone antagonists (GnRH antagonists) are a class of medications that antagonize the gonadotropin-releasing hormone receptor (GnRH receptor) and thus the action of gonadotropin-releasing hormone (GnRH). They are used in the treatment of prostate cancer, endometriosis, uterine fibroids, female infertility in assisted reproduction, and for other indications. Some GnRH antagonists, such as cetrorelix, are similar in structure to natural GnRH (a hormone made by neurons in the hypothalamus) but have an antagonistic effect, while other GnRH antagonists, such as elagolix and relugolix, are non-peptide and small-molecule compounds. GnRH antagonists compete with natural GnRH for binding to GnRH receptors, thus decreasing or blocking GnRH action in the body.
The Meiji government assured the foreign powers that it would follow the old treaties negotiated by the bakufu and announced that it would act in accordance with international law. Mutsuhito, who was to reign until 1912, selected a new reign name—Meiji, or "Enlightened Rule"—to mark the beginning of a new era in Japanese history. To further dramatize the new order, the capital was relocated from Kyoto, where it had been situated since 794, to Tokyo (Eastern Capital), the new name for Edo. In a move critical for the consolidation of the new regime, most daimyōs (feudal lords) voluntarily surrendered their land and census records to the Emperor in the abolition of the Han system, symbolizing that the land and people were under the Emperor's jurisdiction. Confirmed in their hereditary positions, the daimyo became governors, and the central government assumed their administrative expenses and paid samurai stipends. The han were replaced with prefectures in 1871, and authority continued to flow to the national government. Officials from the favored former han, such as Satsuma, Chōshū, Tosa, and Hizen staffed the new ministries. Formerly old court nobles, and lower-ranking samurai, replaced bakufu appointees and daimyo as a new ruling class appeared.
During pregnancy, especially during the first trimester, consumption of retinol in amounts exceeding 4,500 μg/day increased the risk of birth defects, but not below that amount, thus setting a "No-Observed Adverse-Effect Level" (NOAEL). Given the quality of the clinical trial evidence, the NOAEL was divided by an uncertainty factor of 1.5 to set the UL for women of reproductive age at 3,000 μg/day of preformed vitamin A. For all other adults, liver abnormalities were detected at intakes above 14,000 μg/day. Given the weak quality of the clinical evidence, an uncertainty factor of 5 was used, and with rounding, the UL was set at 3,000 μg/day. For children, ULs were extrapolated from the adult value, adjusted for relative body weight. For infants, several case studies reported adverse effects that include bulging fontanels, increased intracranial pressure, loss of appetite, hyperirritability and skin peeling after chronic ingestion of the order of 6,000 or more μg/day. Given the small database, an uncertainty factor of 10 divided into the "Lowest-Observed-Adverse-Effect Level" (LOAEL) led to a UL of 600 μg/day.
Sources: en.wikipedia.org
Storage time depends on peptide sequence, concentration, solvent, and temperature. No single shelf life applies to all peptides. Stability should be determined by analytical testing for the specific preparation.
Aliquots limit the number of freeze-thaw cycles a solution undergoes. Repeated temperature changes can cause aggregation, precipitation, or loss of peptide to container surfaces. Single-use portions also reduce contamination risk when handled aseptically.
Some amino acid side chains, such as tryptophan and tyrosine, can undergo photo-oxidation. Amber vials or foil wrapping are used to reduce light exposure in laboratory settings. The sensitivity varies widely among peptides.
Storage time varies with peptide sequence, concentration, solvent, and temperature. No single duration applies to all peptides, and a clear solution can still degrade without a visible change.